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ABSTRACT  
Nanoparticle based technologies improve the efficiency and speed of already existing processes.The larger size materials and reagents which 
are in reactive form, can be nanosized to give efficient output. Chitosan and the carboxy methyl chitosan nanoparticles were prepared by using 
solvent evaporation nanoprecpitation method, loaded with mefenamic acid, (anthranilic acid derivative) a poorly aqueous soluble drug. 
Mefenamic acid, if used as conventional dosage form, duration of action was 6 hours; when the drug loaded into Chitosan and the carboxy 
methyl chitosan nanoparticles the drug release profile was up to 26hrs. The particle size, entrapment efficiency, poly dispersity index, drug 
loading, drug release profiles of mefenamic acid were compared for both nanoparticles and it was observed that carboxy methyl chitosan 
nanoparticles released mefenamic acid more effectively than chitosan nanoparticles. 
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1.0 INTRODUCTION 
1.1   Nanoparticles  
International Organization of Standardization (ISO) in 2008, 
defined nanoparticles as that all the Cartesian dimensions 
should be less than 100nm. ISO defined nano discs, 
nanoplates as two dimensional nano objects; nano fibers and 
nanotubes as one dimensional nano objects. As per the 
European Union commission in 2011, definition of  
nanoparticle is ‘a natural, manufactured, incidental material 
containing particles, in an unbound state or as an 
agglomerate or as an aggregate and where of 50% of or more 
of the particles in the number size distribution one are more 
external dimensions in the size range of 1nm-100nm. 
1.2   Nanodrug delivery system 
Preparation of nanoparticles are generally applicable to the 
drugs which are poorly aqueous  soluble, the solubility can 
be increased by size reduction process, this can be done by 
various methods like milling, high pressure homogenization, 
high temperature evaporation, vacuum deposition1. These 
nanonization methods are useful to increase the 
bioavailability of drug to the target site2. Nanosized 
molecules can target the drug to the specific site without 
affecting the normal cell line3. Nanoparticles surface is 
covered with polymers or ligands so that they can identify 
and conjugate with disease site and release the drug at a 
constant rate and can cure the disease4.  
Studies have been done on animal models in vivo and 
systemic cell culture in vitro reveals the toxicity of 
nanopaticles includes respiratory system, skin, lungs, brain, 
and reproductive toxicity5. Due to very less size of 
nanoparticles, possess more free energies, thus causing 
aggregation and agglomeration at targeted site. If these 
drugs are insoluble in biological origin (they may reach other 
than targeted site) may affect internal organs during their 
exposure6,7. Negative effects like new toxins and 
environment pollutants may be produced by nanotechnology 
process8.  
1.3    Chitosan   
Chitin and chitosan have similar structure. Chitosan is a 
linear polysaccharide composed of randomly distributed β-
(1-4)-linked D-glucosamine (deacetylated unit) and N-acetyl-
D-glucosamine (acetylated unit). Chitosan is produced 
commercially by deacetylation of chitin, this process is never 
complete. Chitin is soluble in glacial acetic acid, hydrochloric 
acid, nitric acid, perchloric acid, phosphoric and formic acid 
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after stirring at certain temperature9,10, Insoluble in water 
and other organic acids and bases. Unlike chitin, chitosan is 
hydrophilic polymer. In chitosan reactive amino groups 
protonated in acids with pKa less than 6.2 makes chitosan 
soluble. Chitosan is biocompatible, immunoadjuvant, non-
immunogenic, nontoxic, inexpensive, water soluble, stable 
after administration, applicable to a broad category of 
drugs11.  
Over years liposomes are used as drug carriers for targeted 
drug delivery. But these liposomes have poor reproducibility, 
stability and low drug entrapment activity. To overcome this 
problem polymeric nanoparticles  have been prepared to get 
better stability profiles and reproducibility and are taken as 
alternative drug carriers12.           
Poor stability is major limiting step in the preparation of 
chitosan nanoparticles. To maintain stability, temperature, 
environmental factors can be maintained optimized and with 
a suitable stabilizer; chitosan structure can be changed with 
proper ionic or chemical compound13. Another limitation of 
chitosan nanoparticles is the poor solubility14. Unmodified 
chitosan nanoparticles can encapsulate some hydrophilic 
drugs. Modified chitosan nanoparticles can encapsulate 
hydrophobic drugs. So poor solubility is major problem for 
some drugs in preparation of chitosan nanoparticles13. In 
most of the cases, in vitro studies show efficient results but 
failed to show the same in vivo15. 
Finally, financial support to the industries as well as to the 
patients to be taken into consideration, due to expensive 
protocols to be followed in the preparation of NPs, and cost 
of nanomedicine in the markets16. 
1.4     Carboxy Methyl Chitosan (CMC)  
Carboxy methyl chitosan is derivative of chitosan. Solubility 
is more when compared with chitosan. Chitosan solubility is 
very less at pH>6, but for the applications in preparation of 
pharmaceutical products, solubility plays major role and 
important factor.  Chitosan derivative is prepared to increase 
the solubility. Chitosan is converted to carboxy methyl 
chitosan by direct alkylation process as these carboxy methyl 
moieties will change the properties of chitosan17.This type of 
chemical modification by direct alkylation will add carboxy 
methyl groups to two–OH groups (primary& secondary 
alchohol) and one amino group18.The extent of water 
solubility depends on degree of substitution with 
carboxymethylation. As chitosan is converted into 
Carboxymethyl chitosan, it will change its physical and 
biological properties like moisture retention, chelating, 
sorption, cell functioning, antioxidant, antibacterial, anti 
apoptotic etc19. Carboxymethyl chitosan is used in different 
drug delivery systems like in DNA drug delivery as 
permeation enhancer, pH responsive drug delivery. n- 
Carboxymethyl chitosan was first prepared and developed 
by Muzzarelli in 1982, it was tested, used as ingredient in 
cosmetic and biomedical field20,21,22. 
 
 
Figure1.1: Synthesis of carboxytmethyl chitosan 
 
1.5    Mefenamic acid 
Mefenamic acid is non-narcotic, non-steroidal anti-
inflammatory drug. It is used in the treatment of arthritis, 
pain, migraine associated with heavy menstruation, pain 
after surgical operations. It is anthranilic acid derivative. 
 
Fig. 1.2: Molecular structure of Mefenamic acid 
It is Greyish white odour less, microcrystalline powder; 
Molar mass-241.285;Water solubility-0.004% at pH-7.1; 
Formula-C15H15NO2; Chemical Name-N-2,3 
xylylanthranilic acid; Melting point2300-2310C; Metabolism-
Hepatic; Mechanism of action is not clearly known, like other 
NSAIDs, inhibits COX-1&COX-2, potent inhibitor of 
prostaglandin synthesis, analgesic, antipyretic, anti-
inflammatory. 
Dose required is 500mg followed by 250mg for every 6 
hours, not exceeded for one week. 
 
 
1.5.1    Pharmacokinetics of Mefenamic Acid 
Administered orally, distributed in protein bound form, 
metabolised in liver, metabolites are excreted mainly in the 
urine. Onset of Action- 1-2 hrs; Duration of Action- 6 hrs; 
Half Life -2-4 hours.Side Effects are nausea, vomiting, 
anorexia, diarrhoea, gastrointestinal bleeding, abdominal 
distress , constipation, peptic ulcer, dyspepsia, headache, 
flatulence, insomnia, drowsiness, rash, aplastic anaemia, 
thrombocytopenia, dizziness; Contra-indicated in patients 
with hypersensitivity, inflammatory bowel disease, peptic 
ulcer, pregnancy, breast Feeding, below 14 years of age. 
Special Precautions- Hepatic & Renal impairment, 
Hypertension, Gastrointestinal diseases, Pre-existing 
asthma, impairment, Myocardial infarction, Heart failure, 
Patient on anticoagulant therapy, Stroke 
Old Age -Use with caution; Neonates- used only to close the 
patent ductus arteriosus as IV form only  
Indications: Muscular aches, Primary Dysmenorrhoea, 
Headaches, Acute gout, Dental pain, Patent ductus 
arteriosus ; Storage - Store at room temperature in a tightly 
closed light resistant container. 
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2.0 MATERIALS AND METHODS 
2.1    Chemicals 
Standard chitosan was purchased from Chemica and 
Biochemica. Mefenamic acid and other chemicals 
(chloroacetic acid, sodium hydroxide), solvents (2-propanol 
and methanol), reagents, buffers used were of analytical 
grade; purchased from standard manufacturers. 
2.2  Synthesis of Carboxy Methyl Chitosan (CMC) 
2 g of Chitosan suspended in 20ml of 50 % (w/v) sodium 
hydroxide was left swelling for 1 hour at room temp and 
kept for alkalization for 12 h at -20 °C, then thawed at room 
temperature. This alkali chitosan was suspended into 50ml   
of   2-propanol solution and the mixture was stirred on 
magnetic stirrer for 30 min and then in water bath shaker at 
50°C. 10g of Chloroacetic acid dissolved in 30 ml of 
isopropanol was added drop wise over a period of 30 min. 
Reaction mixture was stirred for 12 hours in a water bath at 
50°C. Then the liquid fraction was decanted and 100ml of 
methanol was added to the resulting slurry. The suspension 
was neutralized using glacial acetic acid. Then the mixture 
was filtered and washed several times with methanol. The 
resulting CMC was purified by dissolving in deionized water 
and filtered to remove undissolved residues. The resultant 
solution was precipitated in addition of methanol. Finally the 
pure product was separated by filtration, rinsed with 
methanol, vacuum freeze dried and stored in desiccators 
until further use.  
  
 
Figure-2.1- N- and O-carboxymethylation of chitosan 
 
2.2.1   Characterization of CMC by degree of substitution 
The degree of substitution of CMC was determined by 
potentiometric titration. CMC was dissolved in distilled 
water and the solution was adjusted to pH < 2 by addition of 
hydrochloric acid. Then, the CMC solution was titrated with 
0.1M aqueous sodium hydroxide and the pH value of the 
solution was simultaneously recorded. The amount of 
aqueous sodium hydroxide was determined by the second 
order differential method. The degree of substitution (DS) 
was calculated as follows:                   
   
         
       
 
V1=NaOH volume at pH-3, V2=NaOH volume at pH-3.8, 
V3=NaOH volume at pH-5, DD (degree of deacetylation of 
chitosan); Where Vsodium hydroxide and Csodium 
hydroxide are the volume and molarity of aqueous sodium 
hydroxide, respectively; mCMC is the mass of CMC (g), and 
161 and 58 are the molecular weight of glucosamine 
(chitosan skeleton unit) and a carboxymethyl group, 
respectively.  
2.3    Estimation of Mefenamic acid 
UV visible spectroscopic method for analysis of Mefenamic 
acid was adopted in present work. An accurately weighed 
quantity of Mefenamic acid (100mg) was dissolved in 100 
mL of 7.4 buffers to generate a stock solution having 
concentration of 103 μg /mL. Stock solution (10 mL) was 
further diluted to 100 mL to produce standard solution 
having concentration of 102μg/mL. The standard solution 
was serially diluted with 7.4 buffer to get working standard 
solutions having concentration of 2, 4, 6, 8, 10 μg/mL. The 
absorbance of the solutions was measured at 285.0 nm using 
double beam UV visible spectrophotometer against 7.4 
buffer as a blank.  
2.4    Drug Excipient Compatibility Study 
Drug and excipients were mixed and placed at room 
temperature for 24 hours. The presence of any drug-
polymer interaction was studied by FT-IR spectroscopy.  
Fourier-transform infrared spectroscopy 
To examine possible chemical interactions of MFA-CS NPs 
and interactions of MFA-CMC NPs, Fourier-Transform 
Infrared Spectroscopy (FT-IR) was used. The IR spectra of 
Chitosan, CMC, MFA, MFA-CN NPs, MFA-CMC NPs were 
recorded using an FT-IR spectrophotometer (FT-IR Nicolet-
380, Thermo Fisher Scientific, Madison, USA). Samples were 
mixed with potassium bromide (spectroscopic grade) and 
compressed into disks using a hydraulic press before 
scanning from 4000 to 600 cm-1. Data were analyzed using 
FT-IR solution software (version 1.10). 
2.5 Formulation of MFA-chitosan nanoparticles (MFA-
CSNPs) and MFA-CMC nanoparticles(MFA-CMC NPs) 
MFA-CSNPs and MFA-CMC NPs were prepared   by solvent 
evaporation and nano-precipitation techniques. The 
influence of different independent variables as Chitosan 
concentration (%), tween 80 concentration (%) and 
sonication time (min) were evaluated on particle size (nm), 
drug loading (%) and in vitro drug release (%) were 
investigated.  
Chitosan, CMC containing mefenamic acid-NPs were 
prepared using combined technique of solvent evaporation 
and nanoprecipitation technique with slight modification23. 
This was a two-step process, in the first step; emulsification 
of the polymer solution into aqueous phase containing a 
surfactant was done. Then in the second step evaporation of 
polymeric solvent was carried out, inducing polymer 
precipitation of the nanoparticles24. The calculated 
quantities of chitosan/Carboxy methyl chitosan and tween 
80 and PVA were varied according to the experimental 
design. For the preparation of MFA-CNPs concentrations of 
chitosan (2%,3.5%,5%), tween 80(2%,4.5%,7%), sonication 
time (3min,5min,7min) were used as low, medium, high 
levels of independent variables. For the preparation of MFA-
CMC nanoparticles concentrations of chitosan (2%,4%,6%), 
tween 80 (3%,5%,7%), sonication time (2min,5min,7min) 
were used as low, medium, high levels of independent 
variables. Chitosan was dissolved in an organic solvent 
acetone (10 mL) and separately tween 80 dissolved in 
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double distilled water. The organic solvent was added slowly 
to the aqueous phase containing tween 80 with a constant 
stirring on magnetic stirrer at room temperature. The 
evaporation of the organic solvent was performed at a 
temperature range of 65-800C which involves precipitation 
process lead to formation of nanoparticles. The obtained 
nanoparticles were ultra sonicated for different time interval 
(3-7 min.) at 60-80 KHz amplitude) for 1 cycle and allowed 
to cool at room temperature. The developed MFA-CSNPs and 
MFA-CMC NPs were lyophilized using the freeze dryer at a 
chamber pressure (20pa) and cold trap temperature (-
120ºC) in the entire process. The study was performed for 
24 h for freezing, 4 h for primary drying at 0ºC, followed by 
10ºC for 2 h and 15ºC for 1.5 h and secondary drying at 25ºC 
for 3 h. Mannitol (3%) was added as a cryoprotectant to 
avoid lysis of nanoparticles25. 
2.6   Evaluation of Nanoparticles 
2.6.1  Particle size and size distribution 
The average particle size and size distribution(PDI) of 
mefenamic acid loaded nanoparticles of Chitosan and CMC 
were determined by dynamic laser scattering (DLS) 
technology using a Zeta sizer Nano ZS(Malvern instruments, 
Malvern, UK). The nano suspensions were suitably diluted 
with ultrapure water and sonicated for 2 min to form a 
uniform dispersion before placing the sample in quartz 
cuvette. The hydrodynamic diameter of particles was 
measured with a He-Ne laser at a scattering angle of 900at 
250C. Each sample was determined three times and the 
obtained results were expressed as the mean size of particle 
± SD. 
2.6.2   Measurement of surface charge 
 The zeta potential of the nanoparticles was determined by 
an electrophoretic light scattering technique using a 
Zetasizer Nano ZS (Malvern Instruments Ltd., UK). A diluted 
sample of nanoparticles in water was allowed to stabilize at 
25 0C and was placed in the clear disposable zeta cells. Zeta 
potential was obtained based on the electrophoretic mobility 
between the electrodes. The experiments were performed in 
triplicate and the results were expressed in millivolts (mV) 
2.6.3 Surface morphology 
The surface morphology of the nanoparticles was observed 
by scanning electron microscopy. Sample preparation was 
done by placing a drop of the nanosuspension on an 
aluminium stub. The particles were allowed to settle and the 
excess of the liquid in suspension sample was removed with 
a capillary. The sample was then coated with 30nm layer of 
gold using JEOL JFC 1100E sputter coater for 30s and viewed 
under SEM (JSM 840A, JOEL, Japan). 
2.6.4   Entrapment Efficiency& Drug loading 
Entrapment efficiency (EE%) and drug loading (DL%) of the 
developed MFA-CSNPs and MFA-CMC 
NPs were determined by double beam UV Spectroscopy. The 
prepared nanoparticles were subjected to centrifugation at a 
speed of 10,000 rpm (Remi centrifuge, Mumbai, India)  for 
20min  and the free drug content in the supernatant was   
separated and the separated NPs were solubilised in 
appropriate medium(methanol) and filtered through a 0.22 
μm PVDF filter/ultra filter (Pall Life Sciences, Mumbai, 
India). The supernatant was collected and diluted with an 
appropriate solvent (methanol) to analyze using UV-
spectrophotometer at 285 nm. Consequently, the EE% and 
DL% were calculated by the following formula: 
    
                                        
                    
     
 
             
                                        
                               
     
2.6.5 Drug release Profile 
 The drug release study of chitosan and CMC nanoparticles 
was performed separately with activated dialysis bag 
technique (molecular weight 12000g/mol, Sigma, MO, USA) 
with slight modification from suggested methods. A known 
volume containing nanoparticles in both the formulation 
was placed in a dialysis bag, and both ends were tied to 
prevent any leakage. The bag was dipped in 250ml 
phosphate buffer saline (pH 7.4) as release media at 37 ± 2 
ºC with continuous stirring at 50 rpm25.The release samples 
(1ml) were withdrawn at predetermined time interval and 
were filtered through 0.22µm  PVDF Syringe filter. The 
amount of drug release was calculated by using UV-
spectrophotometer at 285 nm using buffer (pH 7.4) a blank 
sample. 
3.0 RESULTS 
3.1 Results of synthesis and characterization of CMC                  
CMC was characterized by potentiometric titration. By this 
titration one can conclude that the percentage of carboxy 
methyl groups added to the chitosan.Figure-3.1- The 
potentiometric titration curves of four Carboxy methyl 
chitosan solutions. Since protonated chitosan was not 
considered in the study, there is no point after pH 7.0. It was 
clearly shown that the range of titration jumps were around 
pH 3.0–5.0 and the inflection point’s are located at pH 3.80, 
thus this point was used as the titration end-point in the 
solution. The titration end-point pH 3.80 cannot be applied 
to all CMC samples because of the different origins of 
samples. In addition, the pH value responded from the 
composite glass electrode lags behind the pH true value and 
reagent blank error can affect the result of analysis26,27.  
   
              
       
 
V1=NaOH volume at pH-3=5, V2=NaOH volume at pH-
3.8=5.8, V3=NaOH volume at pH-5=6.8, DD (degree of 
deacetylation of chitosan)=0.64 
 
Figure-3.1- Degree of Substitution of Carboxy methyl 
chitosan 
3.3   Results of Estimation of Mefenamic acid 
UV visible spectroscopic method for analysis of Mefenamic 
acid was adopted in present work.   An accurately weighed 
quantity of Mefenamic acid (100mg) was dissolved in 100 
mL of 7.4 buffer to generate a stock solution having 
concentration of 103 μg /mL. Stock solution (10 mL) was 
further diluted to 100 mL to produce standard solution 
having concentration of 102μg/mL. The standard solution 
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was serially diluted with 7.4 buffer to get working standard 
solutions having concentration of 2, 4, 6, 8, 10 μg/mL. The 
absorbance of the solutions was measured at 285.0 nm using 
double beam UV visible spectrophotometer (Figure-3.2) 
against 7.4 buffer as a blank. The plot of absorbance v/s 
concentration (μg/mL) was plotted (Figure 3.3) and data 
was subjected to linear regression analysis in Microsoft 
excel. 
 3.3.1      Preparation of standard calibration curve of 
Mefenamic acid in   7.4  buffer    at  285  nm 
Calibration curve of Mefenamic acid was developed in 0.1 N 
HCI  at 285.0 nm wave length. Mefenamic acid  in 7.4  buffer 
showed good linearity (r2=0.990) and intercept 0.010 over 
the concentration range of 2-10 μg/ml at λmax 285 nm. The 
data for calibration curve are shown in Table 3.3 and the 
calibration curve was shown in Figure 3.3 . 
 
Figure 3.2 Spectra   of   Mefenamic Acid By UV-
Spectroscopy 
Table 3.1 Standard curve   of   Mefenamic Acid in   7.4  
Buffer   at  285  nm 
S.No. Concentration(µg/ml) Absorbance 
1 2 0.1177 
2 4 0.1764 
3 6 0.2688 
4 8 0.3684 
5 10 0.4717 
 
 
Figure 3.3- Standard curve   of   Mefenamic Acid  in   7.4  
Buffer   at  285  nm 
3.4   Results of evaluation of mefenamic acid loaded 
chitosan nanoparticles 
3.4.1  FTIR Results  of Mefenamic acid, Chitosan, MFA- 
CSNP  
FT-IR spectroscopy was used to analyze   the possible 
interactions between the drug and polymers used to form 
MFA loaded CSNPs. The FTIR spectra of MFA, Chitosan and 
CSNPs formulations were represented in Figure-3.4  There 
are primarily determinant peaks of Chitosan around 3433 
cm−1 (-OH and eNH2 stretching), 2876 cm−1 (-CH 
stretching), 1594 cm−1 (-NH2 stretching), 1396 cm−1 (-CN 
stretching), 1018 cm−1 (CeOeC stretching), and 615 cm−1 
(pyranoside ring stretching vibration). In addition, in 
preparation of CSNPs, the peak of 3433 cm−1becomes wider, 
representing that hydrogen binding has been introduced in 
Chitosan in nanostructure. The peak of 1594 cm−1 for eNH2 
shifted to around 1572 cm−1and a new sharp peak at 1700 
cm−1appeared, which can be explained by the interaction of 
NH2 of Chitosan. Compared with the spectrum of MFA, in the 
spectrum of MFA/CSNPs, the absorption peak of about 1632 
cm−1 (carboxyl group) shifted and a new shoulder peak of 
1572 cm-1 (carboxyl salt) appears. It seems that hydrogen 
bonds formed between OH groups of the MFA and those of 
Chitosan and electrostatic interaction taken place between 
COO- of the drug and NH3 þ of chitosan. Moreover, the 
increase in MFA concentration leads to appearance of MFA 
characteristic absorption peaks at high intensities. On the 
other hand, using a low MFA weight ratio in the NP (F1) 
caused the appearance of these characteristic peaks, but at 
low intensity. The results of FTIR are in agreement with 
previous studies. 
 
 
Figure-3.4.1- FTIR  of  Mefenamic acid 
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Figure-3.4.2- FTIR of Chitosan 
 
 
Figure-3.4.3- FTIR of optimized formulation of MFA-
CSNP 
3.4.2    Effect of concentration and sonication time of 
chitosan on particle size, PDI, EE% and DL% of 
formulations of MFA loaded chitosan nanoparticles 
The above results depicted the average size of different 
chitosan loaded nanoparticles and the corresponding 
polydispersity index (PDI) was shown in Table 3.2. The size 
of  ranged from 150  to  245 nm;  Based on the 
EPR(enhanced permeability and retention) effect, the 
nanoparticles under 200 nm were the most suitable for 
penetrating the blood vessels into tumor tissue. All of the 
three Chitosan based nanoparticles under certain preparing 
conditions could meet this requirement with favourable PDI. 
For the nanoparticle stability the zeta potential should be 
between -25mV to +25mV. Zeta potential of chitosan MFA 
nanoparticle is found to be -1.8mV (Figure-3.6). The 
cumulative particle size is 1241.5 (Figure-3.5). 
The results in Table 3.2, showed the interaction effect of 
chitosan concentration and Sonication time on the EE% and 
DL% of MFA loaded CSNPs. These  result revealed that EE% 
varies from   44.58±3.30%  to 82.65±1.16,  F1 having high 
chitosan concentration and longest sonication time showed 
82.65% Entrapment Efficiency  due to cross linking of  
chitosan with drug. DL% varied from 3.93% to 8.14% This 
could be attributed to the binding of hydroxyl groups of MFA 
to positively charged amino groups on chitosan molecules by 
electrostatic interaction These results might be attributed to 
an increase number of interacting units at higher polymer 
concentrations and to cross-linker levels that lead to the 
observed increase in particle size and decrease entrapment 
efficiency
  
Table 3.2-Particle size of MFA loaded chitosan nanoparticles 
Formulation Chitosan Sonication 
time 
Particle 
size(nm) 
PDI  EE% DL% 
F1 +1 +1 150 ±7.9 0.23±0.02 82.65±1.16 8.14±0.07 
F2 0 +1 210±9.1 0.22±0.03 72.48± 0.45 7.29±0.03 
F3 -1 +1 225±8.1 0.33±0.02 58.41± 0.85 5.86±0.08 
F4 +1 0 187±8.9 0.24±0.01 72.10±1.21 7.24±0.20 
F5 0 0 245±10.1 0.21±0.04 67.50±0.82 6.83±0.03 
F6 -1 0 170±6.9 0.22±0.04 77.12±0.49 7.74±0.04 
F7 +1 -1 175±7.9 0.24±0.03 63.19±0.83 5.93±1.06 
F8 0 -1 164±9.9 0.22±0.01 44.58±3.30 3.93±0.77 
F9 -1 -1 200±9.8 0.23±0.02 78.60±0.49 7.89±0.04 
N=3   (Mean± SD) 
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Figure-3.5- cumulative particle size of MFA loaded CSNPs 
 
 
Figure-3.6- Zeta Report of MFA loaded CSNPs 
 
3.4.3   Morphological studies of MFA loaded chitosan 
nanoparticles 
The morphological characteristics of Mefenamic loaded 
CSNPs were observed by SEM. The nanoparticles were found 
to be a roughly spherical in shape with a smooth surface 
(Fig. 3.7). The part of an aggregation of the CSNPs was 
probably because that the hydrogen bonding gradually 
becomes dominant in the drying process. It also was noticed 
that these CSNPs have a deeper colour in the core and the 
surface (white arrows), indicating that these regions have 
higher electron density distribution. The difference size of 
CSNPs in DLS and SEM might be attributed to that CSNPs 
swell in aqueous media. DLS gives a hydrodynamic diameter 
of nanoparticles, while SEM gives an actual diameter of 
nanoparticles in the dry state. 
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Figure: 3.7- SEM (Scanning Electron micrograph) of Mefenamic acid loaded chitosan nanoparticles 
 
3.4.4    Drug release profile of MFA loaded chitosan 
nanoparticles (F1-F9 formulations) 
The release profiles of MFA from the CS-NPs formulations 
compared to drug solution as a control were illustrated in 
Figure-3.8.2 and Figure-3.8.3. In control 35.4% of MFA was 
released rapidly from the dialysis bag within the first 8 hour. 
Total drug 99.87% is released within 14hours. On the other 
hand, MFA loaded CSNPs showed a biphasic pattern with an 
initial burst drug release followed by a sustained release. 
Regarding CSNPs, MFA was rapidly released within the first 8 
h, followed by a slow release from 8 hr up to 26 hr. The rapid 
MFA releasing was mostly due to the nanoparticles surface 
drugs, which could simply diffuse in the first 8 h. The 
cumulative percentage release of MFA from the CSNPs in the 
first 8 h were about 21%, 28%, 12%, 43%, 27%, 46%, 28%, 
33% and 28% for F1, F2, F3, F4, F5, F6, F7, F8, F9 and F10. 
The release profile of F1 is showing biphasic release having 
linear release kinetics after 8hr up to 26 hrs.  
 
Figure-3.8.1-Drug Release Profile of Control (mefenamic 
acid) and F1-MFA-CSNPs
 
Table 3.3- Drug Release profile of MFA loaded Chitosan nanoparticles 
Time 
(h) 
In-vitro Release % 
F1 F2 F3 F4 F5 F6 F7 F8 F9 Control 
0 0 0 0 0 0 0 0 0 0 0 
8 21 28 12 43 27 46 28 33 28 35.24 
10 36 40 20 55 41 65 40 59 40 68.19 
12 48 57 31 71 59 79 57 78 57 89.77 
14 54 62 39 79 65 83 62 83 62 99.87 
16 69 75 43 89 78 91 75 89 69  
20 83 79 54 99.13 81 100 79 96 73  
24 98 88 72  89  88 100 88  
26 101 99 91  98  99  91  
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Figure-3.8.2- drug release profile of Control, F1-F5 MFA 
loaded CSNPs 
 
Figure-3.8.3- drug release profile of Control,F6-F9 MFA 
loaded CSNPs
 
 
3.5 Results of evaluation of MFA loaded CMC 
nanoparticles 
3.5.1 FTIR results of MFA loaded CMC nanoparticles 
Figure-3.9 showed the representative FT-IR spectrum of 
CMC NPs In the infrared spectra, an interesting 
characterization peak was in the range of 2700 – 3000 cm-1, 
indicating the hydrogen bonding. The hydrogen bonding in 
CMCS polymer was at 2893cm-1  and 2800cm-1  respectively, 
and they shifted to 2989 and 2764 cm-1  after MA was 
encapsulated, The vibration peaks of 1598 – 1410 cm-1, 
corresponding to amide I and II bond, had no obvious shift in 
all formulations. The vibration peak at 1404 cm-1 in CMCS 
could be assigned to the symmetric stretching. 
                                                            
 
Figurre 3.9.1 FTIR of Carboxy methyl chitosan 
 
Figure-3.9.2   FTIR of MFA loaded CMC nanoparticles 
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3.5.2     Effect of concentration and sonication time of 
CMC on particle size, PDI, EE% and DL% of formulations 
of MFA loaded CMC nanoparticles 
The effects of CMC concentration and sonication time on 
particle size and polydispersity index (PDI) of MFA-loaded 
CMC nanoparticles were summarized in Table 3.4. The 
particle size increased linearly from 154 to 201 nm with the 
increase of CMC concentration. These trends were in 
accordance with previously reported results28,29. 
The results from Table3.4 showed that the interaction effect 
of Carboxy methyl chitosan concentration and Sonication 
time on the EE% and DL% of MFA loaded CMC-NPs. These  
results revealed that EE% varies from   59.12±3.30%  to 
86.65±1.16,  F8 having high Carboxy methyl chitosan 
concentration and longest sonication time showed 86.12% 
Entrapment Efficiency  due to cross linking of  chitosan with 
drug. DL% varied from 10.51% to 19.31%. 
This could be attributed to the binding of hydroxyl groups of 
MFA to positively charged amino groups on Chitosan 
molecules by electrostatic interaction, these results might be 
attributed to an increase number of interacting units at 
higher polymer concentrations and to cross-linker levels that 
lead to the observed increase in particle size and decrease in 
entrapment efficiency   
For the nanoparticle stability the zeta potential should be 
between -25mV to +25mV. Zeta potential of chitosan MFA 
nanoparticle is found to be -2.8mV (Figure3.11). The 
cumulative particle size is 13.9nm (Figure-3.10).   
                             
Table 3.4- Particle size and PDI of MFA-CMC-NP 
Formulation 
Code 
CMC 
 
Sonication 
time 
Particle size PDI EE% DL% 
F1 +1 +1 158.7±13.4 0.234±0.0235 59.19±1.38 12.31±1.24 
F2 0 +1 170.3±11.2 0.264±0.0245 79.18±2.19 11.21±1.04 
F3 -1 +1 168.7±12.4 0.234±0.0335 81.52±1.27 10.51±1.03 
F4 +1 0 160.3±11.2 0.264±0.0205 79.52±3.39 11.01±1.64 
F5 0 0 154.7±13.4 0.214±0.0335 82.19±1.69 15.31±0.24 
F6 -1 0 177.3±11.2 0.134±0.0435 80.16±1.44 12.31±1.94 
F7 +1 -1 201.7±13.4 0.278±0.0425 78.02±1.30 19.31±1.29 
F8 0 -1 171.3±10.2 0.134±0.0515 86.12±1.09 18.31±1.38 
F9 -1 -1 159.2±12.4 0.264±0.0235 79.02±1.29 11.31±1.44 
N=3   (Mean± SD) 
 
 
Figure-3.10-Cumulative Particle size graph of   MFA-CMC-NP 
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Figure-3.11-Zeta report of   MFA-CMC-NP 
 
3.5.3       Morphological Results of MFA loaded CMC 
nanoparticles 
MFA-CMC-NPs, prepared in the optimal condition were 
observed using SEM (Figure-3.12) All nanoparticleswere 
spherical or ellipsoidal in shape with a smooth surface and 
well dispersed without aggregation. Spherical particles with 
uniform particle size in the nanoscale formed, ranging from 
154 to 201 nm. The aggregates, usually having a rod shape, 
as observed in the SEM photos were probably formed during 
the drying process. The particle size of nanoparticles 
obtained after cast drying was in good agreement with that 
measured in an acidic aqueous system presented. 
                   
 
Figure-3.12-Scanning electron microscopy   results of MFA-CMC-NP (Mefenamic  acid loaded carboxy methyl chitosan 
nanoparticles) 
 
3.5.4      Drug release profile of MFA loaded CMC 
nanoparticles (F1-F9 formulations) 
The release profiles of MFA from the CMC-NPs formulations 
compared to drug solution as a control were illustrated in 
Figure-3.13.1 and Figure-3.13.2.  72.33% of MFA in control 
was released rapidly from the dialysis bag within the first 8 
hour into solution.Total drug 100.1% is released within 12h. 
On the other hand, MFA loaded CMC-NPs showed a biphasic 
pattern with an initial burst drug release followed by a 
sustained release. Regarding CMC-NPs, MFA was rapidly 
released within the first 8 h, followed by a slow release from 
8 hr up to 26 hr. The rapid MFA releasing was mostly due to 
the nanoparticles surface drugs, which could simply diffuse 
in the first 8 h. The percentage release of MFA from the CMC-
NPs in the first 8h were about 44.02%, 31.72%, 34.22%, 
37.01% ,53%,36.01%,38.33%,61% and 28% for F1, F2, F3, 
F4,F5,F6,F7,F8,F9and F10,The release  profile of F8 is 
showing biphasic release having linear  release kinetics after 
8hr upto  26 hr(Figure-3.13.3). 
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Table: 3.5- Drug Release Profile of MFA-CMC-NP 
Time 
(hr) 
In-vitro Release % 
F1 F2 F3 F4 F5 F6 F7 F8 F9 Control 
0 0 0 0 0 0 0 0 0 0 0 
8 44.02 31.77 34.22 37.01 53 36.01 38.33 61 28 72.33 
10 59.21 48.43 68.03 58.27 61.37 55.01 52.11 63 40 96.32 
12 69.43 62.02 70.11 69.43 65.04 79.12 62.01 71 57 100.1 
14 82.33 75.03 74.19 82.33 71.34 83.12 72.51 72 62 100.5 
16 93.12 72.04 75.01 93.12 73.13 93.12 75 81 69 100.9 
20 98.08 99.04 96.06 98.08 78.05 100 81.09 94 73 100.9 
24 100 100 100 100 92.02 100 88.43 96 88 100.9 
26 100 100  100 100  99 100 91 100.9 
 
 
 
Figure-3.13.1-DR% of F1 to F5 MFA-CMC- NP  
 
Figure-3.13.2—DR% of Control, F6 to F9 MFA-CMC-NP 
 
Figure-3.13.3—Drug Release Profile of F8 MFA-CMC-NP 
and Control 
3.5.5     Comparison of Drug release profiles of MFA 
loaded CMC nanoparticles (Formulation F8), MFA loaded 
Chitosan nanoparticles (Formulation F1) and control. 
The release profiles of MFA from the CMC-NPs formulation 
F8, Chitosan-NPs formulation F1 compared to drug solution 
as a control were illustrated in Figure-3.14.  MFA was 
released rapidly from the dialysis bag within the first hour by 
using the drug solution. On the other hand, MFA loaded CS-
NPs and CMC-NPs showed a biphasic pattern with an initial 
burst drug release followed by a sustained release. In both 
CS-NPs & CMC-NPs, MFA was rapidly released within the 
first 8 h, followed by a slow release from 8 hr up to 26 hr. 
The rapid MFA releasing was mostly due to the nanoparticles 
surface drugs, which could simply diffuse in the first 8 h. In 
case of CN-MFA-NP formulation 1(F1) is 8, 10, 12, 14, 16, 20, 
24, 26 hours 21%, 36, 48, 54, 69, 83, 98, 101% of drug is 
releasing. In case of CMC-MFA-NP formulation F8 release 
profiles are- 61%, 63%, 71%, 72%, 81%, 94%, 96%, 100% at 
8, 10, 12, 14, 16, 20, 24, 26 hours respectively. The release 
profile of F8 of CMC-NPs and F1 of CS-NPs are showing 
biphasic release having linear release kinetics after 8hr up to 
26 h (Figure-3.14).  
 
 
Figure-3.14—Drug Release Profile of Control, F8 of MFA-
CMC-NPs and F1 of MFA-CSNPs 
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4.0 DISCUSSION 
Comparative discussion with previous reviews 
Chitosan is soluble at pKa less than 6, to increase the 
solubility; chitosan derivatives were synthesized as 
Tzeneva30. The solubility depends on degree of substitution 
of carboxy methyl groups, which is useful parameter in many 
applications.  The degree of substitution in CMC was between 
0.40-0.45, it was more water soluble as proved by the chen31. 
The degree of substitution was calculated by potentiometric 
titration in this study as 0.51(DS of CMC was found to be 0.68 
by Vaghani26., 0.6 as per the findings of  Mourya32,  0.89 as 
obtained by Ge33, i.e >0.85, so their preparative method was 
said to be perfect method). So the prepared CMC was more 
water soluble, solubility depends on NaOH concentration and 
useful in drug delivery system, similar results were found in 
case of Mourya32, described that 50% NaOH was the 
optimum alkaline solution which favoured the solubility of 
CMC. Similar results were found by the other 
researchers34,35.  
Chitosan-mefenamic acid (40mg)  and Carboxy methyl 
Chitosan- mefenamic acid (40mg) nanoparticles were 
prepared by solvent evaporation nanoprecipitation method. 
Chitosan, CMC concentrations, tween 80 and sonication time 
are taken as variables. The prepared nanoparticle size, 
Entrapment Efficiency, Poly Dispersity Index, Scanning 
Electron Microscopy, FTIR, Drug release profile are studied. 
These Drug release profile obtained for mefenamic acid 
loaded chitosan nanoparticles (MFA CSNP) were compared 
with that obtained for mefenamic acid loaded carboxy 
methyl chitosan nanoparticles (MFA CMC-NP). MFA CSNP 
entrapment efficiency is ranging from 44.58-82.65%, Drug 
loading capacity was 3.95-8.14, particle size ranging from 
150-245nm. MFA CMC-NP entrapment efficiency was 
ranging from 59.19-86.12%, Drug loading capacity is 10.51-
19.31, particle size ranging from 154-201nm. Due to high 
entrapment efficiency (interaction of OH groups with the 
NH2 groups of CMC) the particle size was lesser and drug 
loading capacity was more than chitosan-MA nanoparticles. 
Drug release pattern for MFA CSNP and MFA CMC-NP are 
showing similar release pattern (i.e initial burst release and 
then sustain release), In case of MFA CSNP formulation 1(F1) 
is 8,10, 12, 14, 16, 20, 24, 26 hours 21%, 36, 48, 54, 69, 83, 
98, 101%  of drug was releasing. In case of MFA CMC-NP 
formulation 7(F7), F8 release profiles were- 38.33, 52.11, 
62.01, 72.51, 75, 81.09, 88.43, 99% and 61, 63, 71, 72, 81, 94, 
96, 100% respectively at 8,10, 12, 14, 16, 20, 24, 26 hours. 
This drug release profile was depend on the sonication time 
and the concentration of drug used. MFA CSNP sustain 
release was observed with high concentration of drug and 
high sonication time used (F1), whereas MFA CMC-NP 
sustain release was observed with high concentration of 
drug with less sonication time used due to the solubility of 
CMC than chitosan. 
5.0 SUMMARY AND CONCLUSION 
Chitosan is biodegradable polymer. Its application is limited 
because of its limited solubility at higher range of pH. To 
overcome this chitosan derivative was prepared by carboxy 
methylation to obtain carboxymethyl chitosan, was more 
soluble in wide range of pH. CMC was characterized by FTIR, 
DS (51%). CMC was having more applications in sustained 
and controlled drug delivery systems. Nanoparticles of 
mefenamic acid loaded chitosan (150-245nm) and CMC 
(150-201nm) were prepared. Drug release profiles were 
compared for both nanoparticles. These CMC nanoparticles 
showed sustain release profile and can release the drug for 
26hours. 
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